MA-BATTERY-VENTURES
Battery Ventures, a global, technology-focused investment firm, today announced a significant investment in Mobius Institute (“Mobius”), a company that specializes in reliability improvement, conditioning-monitoring, and precision-maintenance training and certification.
Mobius delivers its training via public, in-plant, and online training programs and has trained more than 70,000 professionals from 180 countries since 2005. In addition to training, a related entity to the company, Mobius Institute Board of Certification, is an ISO/IEC 17024 and ISO 18436-accredited certification body that provides globally recognized certification to reliability professionals, vibration analysts, ultrasound analysts, thermal imaging, and lubrication specialists worldwide.
Mobius Institute is seen as an authority in the industrial asset-reliability space, which is growing in importance as companies transition to predictive and data-based maintenance regimes to operate more efficiently and meet new sustainability targets. Via its network of training partners, Mobius has trained maintenance and reliability professionals across a wide range of industries with students from Pfizer, Rio Tinto, Abbott, Abbvie, Ford, Coca-Cola, Samsung, ABB, Cargill, Nestle, Siemens, Dow, Amazon, Bayer, Mercedes-Benz, NASA, and Hyundai, among others.
Jason Tranter, the co-founder of Mobius, said he hoped the partnership with Battery will help his company scale to a new level. “My wife, Georgie, and I started the business in our house in 1999 with the goal of making vibration analysis and condition monitoring understandable. We never imagined Mobius Institute growing to this scale with almost 10,000 students trained last year alone,” he said. “Having developed a relationship with Battery over the past several years, I am excited to see Mobius continue to grow under Battery’s ownership as the starting point of a new platform.”
As part of the transaction, Tranter will serve as a technical advisor to Mobius.
Battery’s goal with the transaction is to create a large, innovative, asset-reliability and industrial-services player; the firm expects to build upon Mobius’ strength in asset reliability while expanding the portfolio into the broader market for industrial training, certification, and specialized products & services.
As part of this initiative, Marcus Pillion joins the company as Group CEO to drive M&A and continued organic growth, as well as to oversee integration efforts. Pillion joins Mobius after serving most recently as the CEO of Des-Case before its acquisition by Timken (NYSE: TKR) in 2023. Prior to Des-Case, Pillion had previous executive experience across several asset-reliability and condition-monitoring businesses including TRITEC Performance Solutions, Colfax Fluid Handling, EagleBurgmann, SKF and John Crane.
“I am excited to join forces with Battery, a seasoned industrial-technology investor with extensive experience creating platforms through global M&A,” said Pillion. “Having used Mobius Institute training across all of the companies I previously worked for, I am excited to build upon the global brand Mobius has created as we enter into the next phase of its growth trajectory.”
“We are thrilled to partner with Mobius and its exceptional staff as we pursue the next phase of growth for the business,” said Zack Smotherman, a Battery general partner. “Having followed the asset-reliability and condition-monitoring market for many years, we’ve observed an accelerating trend in predictive maintenance and believe we are still in the early innings of this movement as many industries increasingly adopt these solutions.”
Added Battery Principal Justin Rosner: “We are grateful to Jason for the opportunity to partner with Mobius and excited about the journey ahead as we look to leverage Mobius’s global reputation to improve asset reliability across many industries in the years to come.”
About Mobius Institute
Mobius Institute is a worldwide provider of reliability improvement, condition monitoring, and precision maintenance education to industrial plant managers, reliability engineers, and condition monitoring specialists, allowing plants to be successful in implementing reliability improvement and condition monitoring programs. Mobius delivers its training via public, in-person / onsite, and online education programs with a key advantage being its unique training style that uses innovative 3D animations and software simulations, making complex topics easier to understand. Mobius has trained and certified more than 70,000 industrial professionals from 180 countries since 2005 with thousands more engaged through distance learning programs and Mobius’ online community MOBIUS CONNECT. Learn more at https://www.mobiusinstitute.com/about-mobius-institute/.
About Battery
Battery partners with exceptional founders and management teams developing category-defining businesses in markets including software and services, enterprise infrastructure, consumer tech, healthcare IT and industrial technology and life-science tools. Founded in 1983, the firm backs companies at all stages, ranging from seed and early to growth and buyout, and invests globally from offices in Boston, San Francisco, Menlo Park, New York, London, and Tel Aviv. Follow the firm on X @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240326724392/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom